Want to see WHWK full AI Analyst Report?
Whitehawk Therapeutics (WHWK) Ratios
Whitehawk Therapeutics Ratios
WHWK's free cash flow for Q2 2026 was $-14.53M. For the 2026 fiscal year, WHWK's free cash flow was increased by $0.00 and operating cash flow was $-14.53M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.26 | 3.59 | 4.72 | 9.56 | 9.90 |
| Quick Ratio | 10.26 | 3.28 | 4.48 | 9.46 | 9.90 |
| Cash Ratio | 2.59 | 1.68 | 2.38 | 2.07 | 9.76 |
| Solvency Ratio | -1.41 | -3.56 | -2.41 | -2.33 | -5.11 |
| Operating Cash Flow Ratio | -6.71 | -3.49 | -2.26 | -2.64 | -1.47 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 134.49M | $ 43.45M | $ 97.36M | $ 154.17M | $ 129.77M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.34 | 1.26 | 1.16 | 1.16 |
| Debt Service Coverage Ratio | 0.00 | -419.66 | -310.67 | -255.64 | -55.58 |
| Interest Coverage Ratio | 0.00 | -438.04 | -311.40 | -272.53 | -167.24 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.04 | 0.06 | 0.08 | 0.14 |
| Net Debt to EBITDA | 1.83 | 0.43 | 0.86 | 0.64 | 4.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.36% | -108.04% | -112.44% | -123.43% | -1656.25% |
| EBIT Margin | -288.26% | -249.47% | -295.36% | -387.47% | -3309.02% |
| EBITDA Margin | -287.15% | -248.73% | -294.67% | -386.42% | -3299.64% |
| Operating Profit Margin | -1601.12% | -259.62% | -295.36% | -411.94% | -9930.09% |
| Pretax Profit Margin | -288.26% | -245.13% | -270.04% | -397.69% | -9829.29% |
| Net Profit Margin | -288.26% | -245.13% | -270.04% | -397.69% | -9829.46% |
| Continuous Operations Profit Margin | -288.26% | -245.13% | -270.04% | -397.69% | -9829.46% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 18.00% | 94.42% | 91.43% | 96.54% | 98.98% |
| Return on Assets (ROA) | -13.66% | -90.57% | -49.66% | -32.85% | -69.72% |
| Return on Equity (ROE) | -15.11% | -121.37% | -62.52% | -38.21% | -80.71% |
| Return on Capital Employed (ROCE) | -83.93% | -126.69% | -67.84% | -37.90% | -77.97% |
| Return on Invested Capital (ROIC) | -83.93% | -126.06% | -67.57% | -37.81% | -77.90% |
| Return on Tangible Assets | -13.66% | -90.57% | -49.66% | -32.85% | -71.44% |
| Earnings Yield | -13.75% | -74.57% | -119.18% | -20.95% | -51.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 4.40 | 4.44 | 8.17 | 0.00 |
| Payables Turnover | 0.83 | 25.04 | 8.77 | 9.66 | 3.05 |
| Inventory Turnover | 0.00 | 10.18 | 8.05 | 18.27 | 0.00 |
| Fixed Asset Turnover | 2381.67 | 3.40 | 4.08 | 7.50 | 1.82 |
| Asset Turnover | 0.05 | 0.37 | 0.18 | 0.08 | 0.01 |
| Working Capital Turnover Ratio | 0.08 | 0.36 | 0.19 | 0.10 | 0.02 |
| Cash Conversion Cycle | -440.40 | 104.21 | 85.98 | 26.86 | -119.48 |
| Days of Sales Outstanding | 0.00 | 82.92 | 82.25 | 44.67 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 35.86 | 45.34 | 19.98 | 0.00 |
| Days of Payables Outstanding | 440.40 | 14.58 | 41.61 | 37.78 | 119.48 |
| Operating Cycle | 0.00 | 118.79 | 127.59 | 64.65 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.57 | -2.20 | -2.22 | -2.21 | -2.53 |
| Free Cash Flow Per Share | -1.58 | -2.26 | -2.36 | -2.22 | -2.53 |
| Dividend Paid and CapEx Coverage Ratio | -176.51 | -36.00 | -15.02 | -111.80 | -5.03 |
| Capital Expenditure Coverage Ratio | -176.51 | -36.00 | -15.02 | -111.80 | -487.46 |
| Operating Cash Flow Coverage Ratio | 0.00 | -71.49 | -47.09 | -29.89 | -37.06 |
| Operating Cash Flow to Sales Ratio | -13.64 | -2.29 | -2.45 | -3.26 | -20.02 |
| Free Cash Flow Yield | -65.43% | -71.66% | -115.32% | -17.34% | -10.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.33 | -1.34 | -0.84 | -4.77 | -1.95 |
| Price-to-Sales (P/S) Ratio | 20.96 | 3.29 | 2.27 | 18.98 | 191.29 |
| Price-to-Book (P/B) Ratio | 1.10 | 1.63 | 0.52 | 1.82 | 1.57 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.53 | -1.40 | -0.87 | -5.77 | -9.53 |
| Price-to-Operating Cash Flow Ratio | -1.54 | -1.43 | -0.92 | -5.82 | -9.55 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.41 | 0.09 | 0.06 | -0.00 |
| Enterprise Value Multiple | -5.47 | -0.89 | 0.09 | -4.28 | -1.78 |
| Enterprise Value | 112.20M | 57.58M | -6.44M | 251.46M | 65.86M |
| EV to EBITDA | -5.47 | -0.89 | 0.09 | -4.28 | -1.78 |
| EV to Sales | 15.70 | 2.22 | -0.26 | 16.53 | 58.80 |
| EV to Free Cash Flow | -1.15 | -0.94 | 0.10 | -5.02 | -2.93 |
| EV to Operating Cash Flow | -1.15 | -0.97 | 0.11 | -5.07 | -2.94 |
| Tangible Book Value Per Share | 2.20 | 1.94 | 3.91 | 7.04 | 14.95 |
| Shareholders’ Equity Per Share | 2.20 | 1.94 | 3.91 | 7.04 | 15.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.12 | 0.96 | 0.90 | 0.68 | 0.13 |
| Net Income Per Share | -0.33 | -2.36 | -2.44 | -2.69 | -12.41 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.98 | 0.91 | 1.03 | 2.97 |
| Research & Development to Revenue | 12.73 | 1.96 | 2.01 | 2.15 | 17.56 |
| SG&A to Revenue | 4.17 | 1.41 | 0.00 | 0.00 | 16.53 |
| Stock-Based Compensation to Revenue | 1.38 | 0.42 | 0.49 | 0.63 | 1.88 |
| Income Quality | 4.73 | 0.93 | 0.91 | 0.82 | 0.20 |
Currency in USD
